QUOTES:

“I am extremely excited to be working alongside Shiloh Barfield and Ed LeCluyse again, as well as many other former colleagues now at TRL.  We have worked together either as collaborators or colleagues for many years and I am grateful to be a part of such a dynamic and growing organization.  It is exciting to be involved in so many different aspects of the business, and to be with an organization with such vision and passion for scientific advancement,” said Dr. Tom Rushmore on his new role at TRL.

“It has been wonderful having Tom come onboard with our team.  His vast scientific expertise and charming personality have made him a welcome complement to our dynamic organization.  We are so pleased that Tom has joined TRL.  He has come in with an extraordinary passion for innovation and understands better than anyone I know, the shortcomings faced by so many researchers in drug development,” stated Shiloh J. Barfield, General Manager/EVP at TRL.

ABOUT TOM RUSHMORE PhD

Dr. Rushmore received his doctorate in Biochemistry and Molecular Biology from Thomas Jefferson University, Philadelphia PA, in 1983. As a postdoctoral fellow in Dr. Emmanuel Farber’s laboratory at the University of Toronto, he studied models to understand the mechanism of chemical and diet-induced liver cancer. He joined Merck & Co, Inc. in 1987 in the laboratory of Dr Cecil Pickett, where he contributed to the discovery and study of the Antioxidant Response Element. During his 20 plus years at Merck, he contributed to the development and production of many reagents and technologies used routinely in DMPK studies. He joined Life Technologies in 2009 as a Research Fellow in the Cell Technologies Division. Dr. Rushmore has published more than 85 peer-reviewed articles and reviews in the areas of CYP450 induction and inhibition, drug metabolism, metabolite identification and production, and pharmacogenetics. He was appointed as an Adjunct Associate Professor of Pharmaceutical Sciences at the University of the Sciences in Philadelphia and at Thomas Jefferson University where he lectures on Pharmacogenetics.

ABOUT TRL:

TRL was launched in 2011 as a joint venture with the Hamner Institutes and has recruited a staff of industry-recognized specialists in the areas of cell culture, cell isolations, drug-drug interactions, drug metabolism and disposition, analytical chemistry, stem cell developmental biology, molecular biology, and high content image analysis.

The company offers an array of services focused on drug metabolism, drug-drug interactions, in vivo pharmacokinetics and toxicology, drug characterization, functional genomics, drug transporters, diabetes research, virology, hepatotoxicity and neural toxicology.  TRL is the new leader in freshly isolated and cryopreserved hepatocytes.  Immediate R&D efforts are focused on virology of HCV, media development, and in vitro hepatotoxicity.

Triangle Research Labs, LLC Media Contact:

Shiloh Barfield
Executive Vice President & General Manager
Triangle Research Labs, LLC
6 Davis Drive, P.O. Box 12137
Research Triangle Park, NC USA 27709-2137
(919) 549-3583
shiloh.barfield@triangleresearchlabs.com

The post Triangle Research Labs, LLC (TRL) hires Thomas Rushmore, PhD as Vice President of Scientific Affairs appeared first on Triangle Research Labs.

Early Registration ends August 31, 2012. General Registration ends September 21, 2012.

For additional information, please click here.

To register for this course, please click here.

The post September 24-28, 2012 – The Hamner Institutes Hosts ‘Physiologically Based Pharmacokinetic (PBPK) Modeling and its Applications’ Course appeared first on Triangle Research Labs.

QUOTES:
“I am very excited to be working alongside Dr. Ed LeCluyse again. We had such great success together at CellzDirect for so many years. The reliability of the cells we are producing from our preclinical species is second to none. I am excited to be a part of such a dynamic team and to be partnered so closely with the Hamner Institutes”, said Robert Kaiser on TRL entering the primary hepatocyte space.

“For the last several months we have been optimizing the isolation conditions in our new laboratory and we are very pleased with the quality of the freshly isolated human cells we are providing to partners and are ecstatic with our success rate in producing extraordinary batches of cryopreserved hepatocytes”, said Joel LeCluyse on the quality of the human hepatocytes TRL is now providing to the market.

“Joel and Rob are as good as they come at leading primary hepatocyte isolations. In the last several months I have been amazed at their success rate at producing high quality human cryopreserved hepatocytes as well as the quality of cells they are producing from preclinical species. Their combined expertise, coupled with the our organization mantra to return the industry back to a higher level of hepatocyte quality standards, are key ingredients to the success of TRL and the success of our collaborators.” said Shiloh Barfield, EVP/GM of TRL.

ABOUT ROBERT KAISER:
Robert Kaiser is a drug metabolism scientist with almost 13 years of experience in in vivo and in vitro pre-clinical drug development. Rob spent 3 years working with and training under, Dr. Ed LeCluyse at CellzDirect. During his time as Hepatocyte Isolation Supervisor, he successfully worked to maximize the yield, quality, and reliability of cells obtained from all relevant tox species including, but not limited to human, rat, mouse, dog, and non-human primate.

ABOUT JOEL LECLUYSE:
Joel LeCluyse, began his career as an associate scientist at CellzDirect (the former leader in hepatic products and research) and trained under Dr. Edward LeCluyse in both human and animal hepatic isolations. Joel has over 5 years of mass scale hepatic isolations and cell culture experience with 2 years leading human isolations at Invitrogen after their purchase of CellzDirect in 2008. In 2009, Joel was selected by Invitrogen management to open and lead a hepatocyte isolation laboratory in Warrington, UK. He spent 2 years abroad in leading this team and was instrumental in establishing an ADME/Tox base of operations for Life Technologies. Joel is considered one of the world’s leading hepatocyte isolation and cryopreservation scientists.

ABOUT TRL:
TRL was launched in 2011 as a joint venture with the Hamner Institutes and has recruited a staff of industry-recognized specialists in the areas of cell culture, cell isolations, drug metabolism and disposition, analytical chemistry, stem cell developmental biology, molecular biology and high content image analysis.

The company offers an array of services focused on drug metabolism, drug-drug interactions, in vivo pharmacokinetics and toxicology, drug characterization, functional genomics, drug transporters, diabetes research, virology, hepatotoxicity and neural toxicology. TRL also is becoming the new leader in freshly isolated and cryopreserved hepatocytes. Immediate R&D efforts are focused on 3D culture models, virology of HCV, media development, and in vitro hepatotoxicity.

Triangle Research Labs, LLC Media Contact:
Shiloh Barfield
Executive Vice President & General Manager
Triangle Research Labs, LLC
6 Davis Drive, P.O. Box 12137
Research Triangle Park, NC USA 27709-2137
(919) 549-3583

The post March 26, 2012 – TRL Launches Primary Hepatocyte Business appeared first on Triangle Research Labs.

QUOTES:
“I am extremely excited to be working alongside Shiloh Barfield and Dr. Ed LeCluyse again. We have worked together off and on for some many years and I grateful to be a part of such a dynamic and growing organization. It is thrilling to be involved in so many different aspect of the business and to be afforded the luxury of partnering with all the acclaimed scientists here at TRL and the Hamner.”, said Dr. Ronald Laethem on his new role at TRL.

“We are so pleased that Ron has joined the team. He has come in with an extraordinary energy and passion for his work. His knowledge base on the in vitro ADME and the stem cell areas has been a great addition.”, said Shiloh J. Barfield, General Manager/EVP at TRL.

ABOUT RON LAETHEM, Ph.D.
Ronald Laethem, PhD, is a drug metabolism scientist with almost 20 years of experience in the pharmaceutical and biotechnology arenas. He obtained his PhD from Case Western Reserve University and began his postdoctoral work there under an NIH Metabolism Training Grant. After culminating his career at GlaxoSmithKline as a Section Leader in the US DMPK Division, Dr. Laethem started the Target Independent Primary Screening Department at Amphora Discovery Corp., striving to develop drug metabolism assays using microfluidic platforms. He left this post to help found Hepatotech, Inc. becoming the VP for Contract Research before the company was sold to CellzDirect, Inc. Dr. Laethem has spent the last 8 years at Becton Dickinson Technologies in RTP, NC working to develop and commercialize improved in vitro tools for researchers in the academic and industrial fields.

ABOUT TRL:
TRL was launched in 2011 as a joint venture with the Hamner Institutes and has recruited a staff of industry-recognized specialists in the areas of cell culture, cell isolations, drug metabolism and disposition, analytical chemistry, stem cell developmental biology, molecular biology and high content image analysis.

The company offers an array of services focused on drug metabolism, drug-drug interactions, in vivo pharmacokinetics and toxicology, drug characterization, functional genomics, drug transporters, diabetes research, virology, hepatotoxicity and neural toxicology. TRL also is becoming the new leader in freshly isolated and cryopreserved hepatocytes. Immediate R&D efforts are focused on virology of HCV, stem-cell derived hepatic models, media development, and in vitro hepatotoxicity.

Triangle Research Labs, LLC Media Contact:
Shiloh Barfield
Executive Vice President & General Manager
Triangle Research Labs, LLC
6 Davis Drive, P.O. Box 12137
Research Triangle Park, NC USA 27709-2137
(919) 549-3583

The post February 13, 2012 – TRL hires Ronald Laethem, Ph.D. as Senior Director of R & D appeared first on Triangle Research Labs.

Leading TRL’s operations will be Ivin Silver, Ph.D., formerly director of DMPK (Drug Metabolism and Pharmacokinetics) at GlaxoSmithKline, with more than 20 years of comprehensive experience in the pharmaceutical industry applying in vitro and in vivo DMPK techniques to support both drug discovery and development, and Shiloh Barfield, formerly vice president of sales and marketing for the former venture capital based CellzDirect Inc., the world’s former leader for many years in hepatic drug development services and cell products. Edward LeCluyse, Ph.D., a senior research investigator in the Institute for Chemical Safety Sciences at The Hamner and an adjunct associate professor in the Curriculum in Toxicology at The University of North Carolina at Chapel Hill, with more than 25 years of experience in the fields of pharmacology and toxicology, will supervise the research and development programs.

QUOTES:

“This partnership with PBM Capital Group aligns quite well with our shared global public health vision,” said William Greenlee, president and CEO of The Hamner. “We are delighted that The Hamner will be the home for Triangle Research Labs, and I look forward to the many breakthroughs that will advance predictive drug safety models and accelerate new medicine development.”

“We are pleased to have the opportunity to work in close collaboration with The Hamner on a partnership that we believe will benefit both of us, as well as the field of predictive toxicity testing,” said Paul Manning, CEO of PBM Capital Group. “The Hamner’s reputation for scientific excellence is well known, and we are privileged to be associated with them. It is our belief that this research collaboration will lead to innovative science and advances in developing and gaining adoption of the next generation of predictive tools to aid in chemical toxicology and drug discovery and development. We are pleased that the science being developed at our GigaCyte subsidiary can contribute to these advances. ”

DETAILS:

- TRL has recruited a staff of industry-recognized specialists in the areas of cell culture, cell isolations, drug metabolism and disposition, mass spectrometry, stem cell developmental biology, analytical chemistry, molecular biology and high content image analysis.

- The company offers an array of services focused on drug metabolism, drug-drug interactions, in vivo pharmacokinetics and toxicology, drug characterization, drug transporters, diabetes research, virology, hepatotoxicity and neural toxicology. Immediate R&D efforts are focused on virology of HCV, stem-cell derived hepatic models, media development, and in vitro hepatotoxicity.

- GigaCyte will continue as the cell products division focused on innovative 3-D culture systems, primary hepatocytes, beta-islets, primary and stem cell derived neurons, and newly developed application specific cell culture media. For more information, please visit http://www.gigacyte.com.

ABOUT THE HAMNER INSTITUTES FOR HEALTH SCIENCES:

The Hamner Institutes for Health Sciences is a nonprofit research organization located in the heart of Research Triangle Park (RTP), N.C. The two flagship institutes at The Hamner, the Institute for Chemical Safety Sciences and the Hamner-UNC Institute for Drug Safety Sciences, build upon 37 years of preeminent research in toxicology and human health research to develop and validate new cutting-edge tools for safety assessment. Novel technologies currently being developed include in silico models for predictive toxicology, in vitro models that utilize human cells or cell lines to evaluate perturbations of cellular responses, and in vivo models to elucidate genes that play a role in susceptibility to drug-induced toxicities. The Hamner continues to grow its open, multidisciplinary campus through global partnerships with academia, industry, and government, and remains dedicated to positively impacting human health. For more information, please visit http://www.thehamner.org.

ABOUT PBM CAPITAL GROUP:

PBM Capital Group, LLC. is a private investment firm primarily focused on private equity, publicly traded securities and special opportunities. The firm invests across all stages of corporate development including venture capital, leveraged buyouts, growth capital, and distressed/turnaround, as well as public equity value investing. PBM Capital Group creates long-term value by applying extensive industry knowledge and contacts, providing superior operational expertise, and bringing entrepreneurial spirit to attractive investment opportunities. The firm’s investments span a range of industry sectors, including life science, specialty pharmaceutical, medical devices, health/wellness, and consumer products. PBM Capital creates revolutionary companies with innovative products that can change the world and improve the quality of people’s lives. For more information, please visit http://www.pbmcap.com.

The Hamner Media Contact:

Erin Smith
MMI Public Relations
(919) 233-6600
erin@mmipublicrelations.com
http://www.twitter.com/mmipr
http://www.mmipublicrelations.com

Triangle Research Labs, LLC Media Contact:

Shiloh Barfield

Executive Vice President & General Manager

Triangle Research Labs, LLC

6 Davis Drive, P.O. Box 12137

Research Triangle Park, NC USA 27709-2137

(919) 699-0033

shiloh.barfield@triangleresearchlabs.com

The post October 1, 2011 – The Hamner Institutes And PBM Capital Group Launch TRL appeared first on Triangle Research Labs.